In Silico and In Vitro Studies on the Anti-Cancer Activity of Andrographolide Targeting Survivin in Human Breast Cancer Stem Cells

Human CD24/CD44+ breast cancer stem cells (BCSCs) were treated with andrographolide in vitro for 24 hours. The cytotoxic effect of andrographolide on BCSCs was compared to that on human mesenchymal stem cells.
[PLoS One]
Wanandi, S. I., Limanto, A., Yunita, E., Syahrani, R. A., Louisa, M., Wibowo, A. E., & Arumsari, S. (2020). In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells. PLOS ONE, 15(11), e0240020. https://doi.org/10.1371/journal.pone.0240020 Cite
Full Article
Bookmark

No account yet? Register

0
Share

EMT Transcription Factor ZEB1 Represses the Mutagenic POLθ-Mediated End-Joining Pathway in Breast Cancers

Scientists combined a bioinformatics approach exploring both METABRIC and TCGA databases with CRISPR/Cas9-mediated depletion of the zinc finger E-box binding homeobox 1 (ZEB1) in claudin-low tumor cells or forced expression of ZEB1 in basal-like tumor cells, two TNBC subtypes, to demonstrate that ZEB1 represses DNA polymerase theta (POLθ) expression.
[Cancer Research]
Prodhomme, M. K., Pommier, R. M., Franchet, C., Fauvet, F., Bergoglio, V., Brousset, P., Morel, A.-P., Brunac, A.-C., Devouassoux-Shisheboran, M., Petrilli, V., Moyret-Lalle, C., Hoffmann, J.-S., Puisieux, A., & Tissier, A. (2020). EMT transcription factor ZEB1 represses the mutagenic POLθ-mediated end-joining pathway in breast cancers. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-20-2626 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Secreted Sphingomyelins Modulate Low Mammary Cancer Incidence Observed in Certain Mammals

Researchers described a novel cancer-suppressing mechanism, via the secretion of bioactive factors by mammary cells, that was present in domesticated mammals with a low mammary cancer incidence.
[Scientific Reports]
Ledet, M. M., Harman, R. M., Fan, J. C., Schmitt-Matzen, E., Diaz-Rubio, M. E., Zhang, S., & Van de Walle, G. R. (2020). Secreted sphingomyelins modulate low mammary cancer incidence observed in certain mammals. Scientific Reports, 10(1), 20580. https://doi.org/10.1038/s41598-020-77639-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Effects of Obesity on NK Cells in a Mouse Model of Postmenopausal Breast Cancer

The authors analyzed natural killer (NK) cells and NK cell receptor expression of obese mice in a model for postmenopausal breast cancer. Ovaries were ectomized and a syngeneic and orthotopical injection of 4T1-luc2 mouse mammary tumor cells into the mammary adipose tissue pad was performed.
[Scientific Reports]
Spielmann, J., Mattheis, L., Jung, J.-S., Rauße, H., Glaß, M., Bähr, I., Quandt, D., Oswald, J., & Kielstein, H. (2020). Effects of obesity on NK cells in a mouse model of postmenopausal breast cancer. Scientific Reports, 10(1), 20606. https://doi.org/10.1038/s41598-020-76906-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

The Lingering Mysteries of Metastatic Recurrence in Breast Cancer

Investigators provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.
[British Journal of Cancer]
Riggio, A. I., Varley, K. E., & Welm, A. L. (2020). The lingering mysteries of metastatic recurrence in breast cancer. British Journal of Cancer, 1–14. https://doi.org/10.1038/s41416-020-01161-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Wnt Signaling in Breast Cancer: Biological Mechanisms, Challenges and Opportunities

The authors summarize the main findings concerning the relationship between Wnt signaling and breast cancer and provide an overview of existing mechanisms, challenges, and potential opportunities for advancing the therapy and diagnosis of breast cancer.
[Molecular Cancer]
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities | Molecular Cancer | Full Text. (n.d.). Retrieved November 25, 2020, from https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01276-5 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells

Investigators report the design of a fully retargeted oncolytic herpes simplex virus for preferential infection of breast cancer cells through virus recognition of GFRα1, the cellular receptor for glial cell-derived neurotrophic factor .
[International Journal of Molecular Sciences]
Hall, B. L., Leronni, D., Miyagawa, Y., Goins, W. F., Glorioso, J. C., & Cohen, J. B. (2020). Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells. International Journal of Molecular Sciences, 21(22), 8815. https://doi.org/10.3390/ijms21228815 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53

Using Western blotting and qRT-PCR analyses, investigators revealed that in the T47D and BT20 breast cancer cell lines, astaxanthin inhibited expression of pontin and mutp53, as well as the Oct4 and Nanog cancer stem cell stemness genes.
[Marine Drugs]
Ahn, Y. T., Kim, M. S., Kim, Y. S., & An, W. G. (2020). Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53. Marine Drugs, 18(11), 577. https://doi.org/10.3390/md18110577 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Phoenix Molecular Designs Announces First Patient Dosed in Phase 1b Clinical Trial of PMD-026 Taking Aim at Triple Negative Breast Cancer

Phoenix Molecular Designs announced that the first patient has been dosed in their Phase Ib clinical trial of PMD-026. This RSK targeting trial was a first of its kind in the battle to combat the most aggressive subtype of breast cancer, known as TNBC.
[Phoenix Molecular Designs (PR Newswire LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine

Anixa Biosciences, Inc. announced that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine had been filed with the US FDA.
[Anixa Biosciences, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

7th L’Oréal-UNESCO for Women in Science Middle East Regional Young Talents Program Recognizes Six Exceptional Female Scientists from the GCC

The L’Oréal-UNESCO For Women in Science Middle East Regional Young Talents Program, in partnership with Khalifa University of Science and Technology, awarded six winners in the Post-doctorate Researchers and PhD Students categories where Dr. Lama AlAbdi (KSA), Dr. Isra Marei (Qatar), and Dr. Maryam Tariq Khaleel Alhashmi (UAE) each received EUR20,000 in the Post-doctorate Researchers category.
[L’Oréal-UNESCO (Business Today)]
Press Release
Bookmark

No account yet? Register

0
Share
Share